@article{889a9e8b67334f34af52b74605e7f704,
title = "Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005",
abstract = "Recent publications have suggested that imatinib (Glivec) may be cardiotoxic. We have therefore assessed the largest study on the agent performed in patients with gastrointestinal stromal tumours, randomising a daily dose of 400 mg versus 800 mg. 946 Patients were entered, 942 patients received at least one dose of imatinib. The median time on treatment was 24 months. A total of 24,574 exposure months could be analysed. We could not identify an excess of cardiac events in the study population. In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity.",
keywords = "Cardiotoxicity, GIST, Imatinib",
author = "Jaap Verweij and Casali, {Paolo G.} and Dusan Kotasek and {Le Cesne}, Axel and Peter Reichard and Judson, {Ian R.} and R. Issels and {van Oosterom}, {Allan T.} and {Van Glabbeke}, Martine and Blay, {Jean Yves}",
note = "Funding Information: This study was supported by an unrestricted grant from Novartis Oncology. Novartis was not involved in the writing of this manuscript, but has reviewed its content prior to submission Funding Information: This publication was supported by Grant(s) number 2U10 CA11488-29 (through 5U10 CA11488-34) from the National Cancer Institute (Bethesda, MD, USA). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. ",
year = "2007",
month = apr,
day = "1",
doi = "10.1016/j.ejca.2007.01.018",
language = "English",
volume = "43",
pages = "974--978",
journal = "European Journal of Cancer",
issn = "0959-8049",
number = "6",
}